Free Daily Podcast Summary
BioSpace: Daily Summaries Delivered
by BioSpace
Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.
Latest Episodes
The most recent episodes — sign up to get AI-powered summaries of each one.
- 1 weeks ago18 min
Why investors are taking another look at kidney disease
In this episode of Denatured, you’ll hear from Bruce Culleton, CEO at ProKidney and Demetri Maxim, CEO at Nephrogen. We discuss why kidney disease has long been a hard target for cell and gene therapies, and what new delivery strategies, therapeutic approaches and regulatory clarity mean for commercially viable products.HostJennifer C. Smith-Parker, Director of Insights, BioSpaceGuestsBruce Culleton, CEO, ProKidneyDemetri Maxim, CEO, NephrogenDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.
- 1 weeks ago17 min
Disc’s redemption, China’s rise, Veradermics’ validation, ESMO’s headliners
China cracks down on some biotechnology ownership transfers—but will the new policy impact licensing deals?; Disc Medicine’s Phase 3 data sweep redeems rejected rare disease therapy, teeing up another FDA run; and the ESMO conference gets underway in Madrid this week, with much-anticipated data from Merck and Summit Therapeutics.
- 2 weeks ago16 min
Bonus: Q3 2026 Job Market Update
BioSpace Vice President Chantal Dresner and Angela Gabriel, content manager, life sciences careers, cover what happened in the biopharma job market during the third quarter. They discuss encouraging signs for those looking for their next opportunity, such as improved job postings live on the BioSpace website and a dramatic drop in layoffs. Other topics include signs of industry health, news about job opportunities and advice for the Q4 job hunt.
- 2 weeks ago10 min
The decisions behind scientific progress
In this episode of Denatured, sponsored by Cytiva, Jennifer Smith-Parker speaks to Nicolas Pivet, VP & GM, Manufacturing & Digital Solutions at Cytiva. In this episode, we discuss how biopharma has long invested in more data and visibility, yet many programs still face delays and scale-up surprises. The real challenge isn’t information overload—it’s building confidence in the decisions that steer scientific progress from development through commercialization.This episode is presented in partnership with Cytiva. HostJennifer Smith-Parker, Director of Insights, BioSpaceGuestNicolas Pivet, VP & GM, Manufacturing & Digital Solutions, CytivaDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations
- 2 weeks ago19 min
J&J’s disappointing Q3, RevMed’s subgroup data, BMS’ ‘mixed’ results, Caribou’s cutback
Johnson & Johnson beat analyst expectations in the third quarter but left Wall Street wanting more; BMS dominated the news cycle on Monday with a Phase 3 win validating its $4.1 billion RayzeBio buy and mixed data in a late-stage pulmonary fibrosis trial; Revolution Medicines’ newly approved pancreatic cancer drug works better for patients with certain mutations; and Caribou Biosciences may be on its way out.
- 3 weeks ago22 min
Beyond equity: Why venture debt is reshaping European biotech
In this episode of Denatured, you’ll hear from Jennifer McMahon, partner at Seroba and Joey Mason, venture partner at Claret Capital. We dig into how venture debt buys time when equity can’t — and how Europe’s funding gaps, tranching habits and slower urgency shape who uses it well.HostJennifer C. Smith-Parker, Director of Insights, BioSpaceGuestsJennifer McMahon, Partner, SerobaJoey Mason, Venture Partner, Claret CapitalDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.
- 3 weeks ago24 min
Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, more
New data for Genmab and AbbVie’s bispecific antibody Epkinly wowed analysts and could set the partners up for an expanded approval in diffuse large B cell lymphoma; deals have flowed steadily this week, including Novartis’ nearly $8 billion bet on mRNA drugs with China’s Abogen Biosciences; and could Sarepta Therapeutics turn things around from last year’s annus horribilis?
- Oct 1, 202620 min
The race for access: How the FAIR Act could reclaim U.S. biotech leadership
In this episode of Denatured, you’ll hear from Max Bronstein, CEO of Aviva Strategies and Teresa Barnes, Chief Executive Warrior of PF Warriors. We dig into why U.S. patients are losing access to rare disease trials happening abroad and how the FAIR Act’s accelerated, harmonized reviews could help the U.S. keep pace while getting lifesaving studies to patients faster.HostJennifer C. Smith-Parker, Director of Insights, BioSpaceGuestsMax Bronstein, CEO, Aviva StrategiesTeresa Barnes, Chief Executive Warrior, PF WarriorsDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.
Get BioSpace summaries in your inbox
Free AI-powered daily recaps. Key takeaways, quotes, and mentions — in a 5-minute read.
Get Free Summaries →Free forever for up to 3 podcasts. No credit card required.
You Might Also Like
Listeners also like.
Stock Movers
Short conversations analyzing today's biggest gainers and losers in global stock markets across major sectors.
Bloomberg Intelligence
Analysis of Wall Street investments and company research by Bloomberg Intelligence experts.
The VPZD Show
Two physicians discuss healthcare, medicine, and policy from a contrarian, middle-ground perspective.
Sourcery
Interviews with top investors, CEOs, and founders.
Galaxy Balance
Explores the intersection of biology, technology, and consciousness through deep conversations with innovators shaping humanity’s future.
Everybody's Business
A weekly look at business news from Wall Street to unusual ventures, with insights from Bloomberg Businessweek journalists.
The Best One Yet
A daily 20-minute podcast breaking down the three key business stories with sharp, accessible takes.
A Shot in the Arm Podcast
Ben Plumley
Solutions with Henry Blodget
Henry Blodget interviews experts in business, tech, and politics about practical solutions for building a better future.
Unbiased Science
Dr. Jess Steier and guests analyze viral health claims using scientific evidence and explain key findings for everyday conversations.
So, Get This
iHeartPodcasts and Bubbler
Moonshots with Peter Diamandis
Exploring breakthrough technologies and their impact on humanity's future.
About BioSpace
Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.
Customized Recaps
AI-powered recaps with compact key takeaways, quotes, and insights.
Straight to Your Inbox
Get key takeaways from BioSpace in a 5-minute read.
Save Hours Every Week
Stay current on your favorite podcasts without falling behind.
Frequently Asked Questions
What is Podzilla's BioSpace daily summary?
It's a free AI-powered email that summarizes new episodes of BioSpace as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
How does the BioSpace podcast summary work?
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
Is this an official BioSpace product?
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by BioSpace.
Can I get summaries of other podcasts too?
Absolutely! The free plan covers up to 3 podcasts, any in the catalog. Basic raises that to 15, Pro to 40 and Max to 100. Browse our full catalog at /podcasts.
How often does BioSpace release new episodes?
BioSpace publishes daily. Our AI generates a summary within hours of each new episode.
What topics does BioSpace cover?
BioSpace covers topics including Science, Life Sciences. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Start getting BioSpace summaries tomorrow morning.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.